LQDA News and Press, Liquidia Technologies Inc. From 05/17/24

2024-05-17 10:17:19 ET Summary Liquidia's stock price has experienced an unjustified selloff, creating a buying opportunity. Potential catalysts include FDA approval of Yutrepia, legal wins on the 327 patent, and positive data readouts on PH-ILD studies. Sales data on Tyvaso a...

2024-05-15 01:22:49 ET Summary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current asse...

2024-05-14 11:05:09 ET Liquidia Corporation (LQDA) Q1 2024 Earnings Conference Call May 14, 2024, 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Dr. Roger Jeffs - Chief Executive Officer Michael Kaseta - Chief Operating Officer and CFO D...

2024-05-14 04:03:12 ET More on Liquidia Liquidia Corporation: A Complicated Tale United Therapeutics motion for restraining order over Liquidia's Yutrepia denied Seeking Alpha’s Quant Rating on Liquidia Read the full article on Seeking Alpha Fo...

MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a c...

2024-05-13 12:11:34 ET More on Liquidia Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript Liquidia Corporation: A Complicated Tale United Therapeutics motion for restraining order over Liquidia's Yutrepia denied Liquidia gains after court win in pa...

2024-05-12 11:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

MORRISVILLE, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in people with pulmonary arterial hypertension (PAH) and pulmonary h...

MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Michael Kaseta, chief operating officer and chief financial officer, will provide an update on the company's business during a fireside chat at the BofA Securities Health Care Confere...

MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and...